Is Buying bioMmune Technologies Inc Here a Winning Strategy?

 Is Buying bioMmune Technologies Inc Here a Winning Strategy?

The stock of bioMmune Technologies Inc (CVE:IMU) is a huge mover today! About 60,000 shares traded hands or 76.41% up from the average. bioMmune Technologies Inc (CVE:IMU) has risen 6.00% since September 28, 2016 and is uptrending. It has outperformed by 1.29% the S&P500.
The move comes after 6 months positive chart setup for the $17.26M company. It was reported on Oct, 28 by Barchart.com. We have $1.47 PT which if reached, will make CVE:IMU worth $29.00M more.

More notable recent bioMmune Technologies Inc (CVE:IMU) news were published by: Marketwired.com which released: “bioMmune Technologies Inc. Announces Appointment of Directors” on December 09, 2015, also Marketwired.com with their article: “BioMmune Technologies Inc. Announces the Appointment of Dr. Karoly Nikolich to …” published on September 24, 2013, Marketwired.com published: “BioMmune Appoints Thomas Gadek, PhD, to Board of Directors” on September 20, 2016. More interesting news about bioMmune Technologies Inc (CVE:IMU) were released by: Marketwired.com and their article: “BioMmune, A 2016 TSX Venture Top 50 Company, Awarded Patent for Calcium …” published on June 29, 2016 as well as Investorideas.com‘s news article titled: “Biotech Stock Directory Update” with publication date: August 14, 2014.

Biommune Technologies Inc, formerly MC Partners Inc, is a Canada biopharmaceutical company. The company has a market cap of $17.26 million. The Firm is a research and development issuer. It currently has negative earnings. The Firm is engaged in the research and development of products for the treatment of cancers, and for improvement of the immune system.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment